🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma

RecruitingNAAges 18 Years - anyAllInstitute of Oncology Ljubljana
NCT07404605 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Cutaneous melanoma frequently develops cutaneous and subcutaneous metastases, which may cause significant morbidity and negatively affect quality of life. Electrochemotherapy (ECT) is an established local treatment modality for cutaneous and subcutaneous tumor lesions that combines the administration of cytotoxic drugs with the application of electric pulses to increase drug uptake into tumor cells. In addition to its direct cytotoxic effects, electrochemotherapy may induce changes in the tumor microenvironment, including immune cell infiltration, vascular alterations, and other biological responses that could influence tumor control. The aim of this study is to evaluate changes in the tumor microenvironment of cutaneous and subcutaneous melanoma metastases following electrochemotherapy with either intravenous bleomycin or intratumoral cisplatin. Tumor tissue samples collected before a

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults aged 18 years or older * Histologically confirmed cutaneous melanoma * Presence of cutaneous and/or subcutaneous metastases eligible for electrochemotherapy * Candidate for electrochemotherapy with intravenous bleomycin or intratumoral cisplatin according to standard clinical practice * Ability to provide written informed consent Exclusion Criteria: * Contraindication to electrochemotherapy or study drugs (bleomycin or cisplatin) * Pregnancy or breastfeeding * Severe comorbidities preventing electrochemotherapy * Inability to comply with study procedures
💊

What it tests

  • Electrochemotherapy
📍

Where

1 site
Institute of Oncology Ljubljana
Ljubljana, Slovenia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy